Document Detail


Circulating aggregated platelets, number of platelets per aggregate and platelet size in chronic dialysis patients.
MedLine Citation:
PMID:  9380237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The accelerated arteriosclerosis of chronic dialysis patients is multifactorial. Both non-uremic patients with atherosclerosis and uremic patients have functional platelet abnormalities. Our aim was to study platelet function in chronic dialysis patients and to correlate the findings with the presence of cardiovascular morbidity. Fifty-three chronic dialysis patients were examined. The presence of risk factors for cardiovascular disease (CVD) was recorded, and the patients were examined for the presence of ischemic heart disease, peripheral vascular disease and cerebrovascular accident. The parameters of platelet function, which were examined with the modified Wu and Hoak method, included platelet number, percentage of totally, reversibly and irreversibly aggregated platelets, average number of platelets per aggregate and percentage of large platelets. Significant differences were found between totally aggregated platelets, reversibly and irreversibly aggregated platelets, the percentage of large platelets (p < 0.0001) and the average number of platelets per aggregate (p < 0.001) in dialysis patients compared with control persons. There was no difference between the 2 groups in platelet count. No differences were found between hemodialysis and peritoneal dialysis groups, and the duration of dialysis treatment had no effect. We conclude that platelet abnormalities evident in chronic dialysis patients are a part of the multifactorial etiology of advanced CVD and may predispose dialysis patients to CVD.
Authors:
J Winkler; J Fuchs; G Morduchowicz; G Boner; J Sulkiss; I Weinberger
Related Documents :
16928607 - Increased platelet reactivity in unstable angina patients is not related to c-reactive ...
9606357 - Acute coronary syndromes: 2. antiplatelet agents.
9115957 - Angiotensin-converting enzyme inhibitors and coronary artery disease.
6665767 - Transcoronary platelet thromboxane a2 formation without platelet trapping in patients w...
8326817 - Purpurogallin as an antioxidant protector of human erythrocytes against lysis by peroxy...
2938647 - Quinidine purpura: evidence that glycoprotein v is a target platelet antigen.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Nephron     Volume:  77     ISSN:  0028-2766     ISO Abbreviation:  Nephron     Publication Date:  1997  
Date Detail:
Created Date:  1997-11-10     Completed Date:  1997-11-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0331777     Medline TA:  Nephron     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  44-7     Citation Subset:  IM    
Affiliation:
Institute of Hypertension and Kidney Diseases, Rabin Medical Center, Petah Tikva, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arteriosclerosis / pathology
Blood Platelets / ultrastructure*
Cardiovascular Diseases / complications,  mortality
Female
Humans
Kidney Failure, Chronic / blood*,  complications,  therapy
Male
Middle Aged
Platelet Aggregation / physiology*
Platelet Count*
Platelet Function Tests
Renal Dialysis / adverse effects*
Risk Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysi...
Next Document:  Silicon-related syndrome in dialysis patients.